NOVABAY PHARMACEUTICALS INC (NBY)
US66987P3001 - Common Stock
NBY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. NBY may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, NBY is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year NBY has reported negative net income.
NBY had a negative operating cash flow in the past year.
NBY had negative earnings in each of the past 5 years.
NBY had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
NBY has a Return On Assets of -184.85%. This is amonst the worse of the industry: NBY underperforms 90.77% of its industry peers.
NBY has a Return On Equity of -503.89%. This is amonst the worse of the industry: NBY underperforms 82.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -184.85% | ||
| ROE | -503.89% | ||
| ROIC | N/A |
ROA(3y)-103.8%
ROA(5y)-95.46%
ROE(3y)-240.85%
ROE(5y)-378.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NBY's Gross Margin of 53.68% is fine compared to the rest of the industry. NBY outperforms 62.56% of its industry peers.
NBY's Gross Margin has declined in the last couple of years.
NBY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.68% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.69%
GM growth 5Y-9.44%
2. Health
2.1 Basic Checks
NBY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NBY has more shares outstanding
NBY has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NBY has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -26.67, we must say that NBY is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -26.67, NBY is doing worse than 87.69% of the companies in the same industry.
A Debt/Equity ratio of 0.34 indicates that NBY is not too dependend on debt financing.
NBY has a worse Debt to Equity ratio (0.34) than 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.34 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -26.67 |
ROIC/WACCN/A
WACC16.33%
2.3 Liquidity
A Current Ratio of 1.67 indicates that NBY should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.67, NBY is doing worse than 72.31% of the companies in the same industry.
NBY has a Quick Ratio of 1.67. This is a bad value and indicates that NBY is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.00, NBY is doing worse than 79.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.67 | ||
| Quick Ratio | 1 |
3. Growth
3.1 Past
NBY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.07%, which is quite impressive.
NBY shows a small growth in Revenue. In the last year, the Revenue has grown by 2.27%.
NBY shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.32% yearly.
EPS 1Y (TTM)57.07%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-70.51%
Revenue 1Y (TTM)2.27%
Revenue growth 3Y14.04%
Revenue growth 5Y3.32%
Revenue growth Q2Q2.39%
3.2 Future
The Earnings Per Share is expected to grow by 42.20% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 22.40% on average over the next years. This is a very strong growth
EPS Next Y87.02%
EPS Next 2Y42.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.83%
Revenue Next 2Y22.4%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NBY. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NBY. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NBY's earnings are expected to grow with 42.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.2%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for NBY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NOVABAY PHARMACEUTICALS INC
NYSEARCA:NBY (4/24/2024, 7:18:50 PM)
After market: 0.0747 0 (-3.36%)0.0773
+0 (+0.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.33M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -184.85% | ||
| ROE | -503.89% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.68% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.34 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.67 | ||
| Quick Ratio | 1 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)57.07%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y87.02%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)2.27%
Revenue growth 3Y14.04%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y